[1]李著艳,马亚琳,龚宝兰△.米非司酮单用与联合宫瘤消胶囊对子宫腺肌症患者的影响[J].西部中医药,2019,32(07):92-95.
　LI Zhuyan,MA Yalin,GONG Baolan.Effects of Only Mifepristone and Its Combination with Gongliuxiao Capsules on the Patients with Adenomyosis[J].Western Journal of Traditional Chinese Medicine,2019,32(07):92-95.
点击复制

米非司酮单用与联合宫瘤消胶囊对子宫腺肌症患者的影响
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
32
期数:
2019年07期
页码:
92-95
栏目:
出版日期:
2019-07-15

文章信息/Info

Title:
Effects of Only Mifepristone and Its Combination with Gongliuxiao Capsules on the Patients with Adenomyosis
文章编号:
1004-6852(2019)07-0092-04
作者:
李著艳，马亚琳，龚宝兰△
十堰市人民医院/湖北医药学院附属人民医院妇科，湖北 十堰 442000
Author(s):
LI Zhuyan, MA Yalin, GONG Baolan△
Shiyan City People′s Hospital /Department of Gynecology, Affiliated People′s Hospital of Hubei University of Medicine, Shiyan 442000, China
关键词:
子宫腺肌症; 痛经; CA125; 米非司酮; 宫瘤消胶囊
Keywords:
adenomyosis;  dysmenorrhea;  CA125;  mifeprinstone;  Gongliuxiao capsules
分类号:
R271
文献标志码:
B
摘要:
目的：探讨非司酮单用与联合宫瘤消胶囊对子宫腺肌症(adenomyosis，AM)患者痛经、子宫体积、CA125及复发率的影响。方法：将AM患者76例用随机数字表法分为观察组与对照组各38例，对照组给予米非司酮治疗，观察组在对照组治疗的基础上给予宫瘤消胶囊治疗，治疗3个月。结果：2组患者子宫体积治疗后小于治疗前(P＜0.05)，观察组治疗后子宫体积小于对照组(P＜0.05)。治疗后2组患者痛经评分均低于治疗前(P＜0.05)，观察组痛经评分低于对照组(P＜0.05)。治疗后观察组与对照组患者血清CA125分别为(15.63±5.29)U/mL和(24.13±4.19)U/mL，低于治疗前的(25.65±5.34)U/mL和(25.64±5.21)U/mL(P＜0.05)，治疗后观察组血清CA125低于对照组(P＜0.05)。观察组与对照组随访6个月的复发率分别为0.0%(0/38)和15.8%(6/38)，观察组复发率低于对照组( χ2=5.398，P＜0.05)。结论：相对于米非司酮，米非司酮联合宫瘤消胶囊治疗AM能缓解患者痛经，促进缩小子宫体积，抑制CA125的表达，减少复发率。
Abstract:
Objective: To discuss the effects of only mifeprinstone and its combination with Gongliuxiao capsules on dysmenorrhea, uterine volume, CA125 and the relapse of the patients suffering adenomyosis(AM). Methods: All 76 patients were allocated to the observation group and the control group using random number table method, 38 cases each group, the control group was treated with mifeprinstone, and the observation group was given Gongliuxiao capsules based on the therapy the control group accepted, the course was three months. Results: Uterine volume of both groups after treating was smaller than that before treating (P＜0.05), the observation group after treating was smaller than the control group in uterine volume (P＜0.05). After treating, dysmenorrhea scores of both groups were less than these before treating(P＜0.05), the observation group was lower than the control group in dysmenorrhea scores(P＜0.05). After treating, CA125 of the observation group and the control group were (15.63±5.29) U/mL and (24.13±4.19) U/mL, obviously lower than (25.65±5.34) U/mL and (25.64±5.21)U/mL before treating (P＜0.05), after treating, the observation group was lower than the control group in serum CA125 (P＜0.05). The relapse rates of the observation group and the control group in six-month follow-ups were 0.0% (0/38) and 15.8%(6/38), the recurrence rate of the observation group was lower than that of the control group( χ2=5.398, P＜0.05). Conclusion: Compared with mifeprinstone, its combination with Gongliuxiao capsules could mitigate dysmenorrhea, promote the reduction of uterine volume, inhibit the expressions of CA125 and reduce the relapse.

相似文献/References:

[1]谷云,李小梅,潘耀军,等.吴克明教授治疗虚寒型原发性痛经的经验[J].西部中医药,2011,24(11):14.
[2]王兆勤.中西医结合治疗女大学生原发性痛经55例临床观察[J].西部中医药,2013,26(01):91.
　WANG Zhaoqin.Clinical Observation on Integrated Traditional Chinese and Western Medicine in Treating 55 Cases of Primary Dysmenorrhea in Undergraduate Students[J].Western Journal of Traditional Chinese Medicine,2013,26(07):91.
[3]顾建军,王令仪.复方阿胶浆用于女大学生月经失调及痛经的疗效调查分析[J].西部中医药,2013,26(11):86.
　GU Jianjun,WANG Lingyi.Therapeutic Effects of Compound EJiao Syrup for Menstrual Disorder and Menalgia of Female Undergraduate[J].Western Journal of Traditional Chinese Medicine,2013,26(07):86.
[4]潘 文.基于数据挖掘的治疗原发性痛经方证与核心药物配伍规律分析[J].西部中医药,2015,28(12):75.
[5]刘丽萍.四物汤合失笑散加味联合吲哚美辛治疗气滞血瘀型原发性痛经40例[J].西部中医药,2013,26(03):103.
　LIU Liping.Modified SiW uTang and ShiXiaoSan Combined with Indomatacin in Treating 40 Cases of Primary Dysmenorrhea of Qi Stagnation and Blood Stasis Pattern[J].Western Journal of Traditional Chinese Medicine,2013,26(07):103.
[6]陈俐禄.数据挖掘中药复方治疗痛经的用药规律[J].西部中医药,2016,29(04):86.
　CHEN Lilu.Medication Rules of Herbal Compounds in Treating Dysmenorrhea Based on Data Mining[J].Western Journal of Traditional Chinese Medicine,2016,29(07):86.
[7]金玉盛,商军安.《傅青主女科》辨治及调摄痛经特点探析[J].西部中医药,2017,30(08):44.
　JIN Yusheng,SHANG Junan.An Analysis on the Features of Differentiating, Treating and Regulating Dysmenorrhea in FuQingZhu NYvKe[J].Western Journal of Traditional Chinese Medicine,2017,30(07):44.
[8]杨艳,李琪,顾骏薇,等.耳穴治疗痛经的文献研究[J].西部中医药,2017,30(12):35.
　YANG Yan,LI Qi,GU Junwei,et al.Literature Study of Ear Acupoint in Treating Dysmenorrhea[J].Western Journal of Traditional Chinese Medicine,2017,30(07):35.
[9]张春花.增损葫芦巴丸治疗子宫内膜异位症所致痛经疗效观察[J].西部中医药,2018,31(05):84.
　ZHANG Chunhua.Clinical Observation on ZengSun HuLuBa Pills in Treating Endometriosis-induced Dysmenorrhea[J].Western Journal of Traditional Chinese Medicine,2018,31(07):84.
[10]陈丽.中西医护理干预在原发性痛经患者中的应用效果[J].西部中医药,2018,31(06):125.
　CHEN Li.Effects of Nursing Intervention of Traditional Chinese and Western Medicine Applied to the Patients with Primary Dysmenorrhea[J].Western Journal of Traditional Chinese Medicine,2018,31(07):125.

备注/Memo

备注/Memo:
收稿日期：2018-03-27*基金项目：国家自然科学基金项目(编号81272866)。作者简介：李著艳(1982—)，男，硕士学位，主治医师。研究方向：妇科肿瘤基础及临床研究。△通讯作者：龚宝兰(1973—)，女，副主任医师。研究方向：妇科内分泌疾病的诊治。
更新日期/Last Update: 2019-07-15